Treating vitamin D insufficiency in primary hyperparathyroidism: a cautionary tale

Area of Science:

• Endocrinology
• Metabolic Disorders
• Nutritional Science

Background:

• Vitamin D deficiency is a widespread issue, often co-occurring with primary hyperparathyroidism.
• Optimal Vitamin D status management in hyperparathyroidism patients lacks established guidelines.
• Pre-operative Vitamin D repletion may offer benefits, but risks require consideration.

Observation:

• A case study involved a 64-year-old male with primary hyperparathyroidism, osteoporosis, and Vitamin D insufficiency.
• The patient received high-dose ergocalciferol (50,000 IU weekly for 8 weeks).
• This treatment led to significant increases in serum calcium and urine calcium.

Findings:

• High-dose Vitamin D supplementation can exacerbate hypercalcemia and hypercalciuria in patients with primary hyperparathyroidism.
• These adverse effects resolved upon discontinuation of Vitamin D therapy.
• The study highlights the potential risks associated with aggressive Vitamin D treatment in this population.

Implications:

• Clinicians should exercise caution when prescribing Vitamin D for patients with primary hyperparathyroidism and deficiency.
• Consideration of modest daily doses (e.g., 1,000 IU) may be a safer approach for Vitamin D repletion.
• Close monitoring of serum and urine calcium levels is recommended during Vitamin D therapy in these patients.